EcoDrugPlus

Melanocortin 4 Receptor

Ensembl ID : ENSDCDG00000034707
Gene Symbol: MC4R
1 Cross references
202 Possible Orthologues:

Melanocortin Receptor 4-Like

Ensembl ID : ENSDCDG00000001145
Gene Symbol: LOC114787840
3 Cross references
153 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSDCDG00000023964
Gene Symbol: MTNR1A
3 Cross references
138 Possible Orthologues:

Melatonin Receptor Type 1a-A

Ensembl ID : ENSDCDG00000002730
Gene Symbol: LOC114788716
3 Cross references
190 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSDCDG00000026639
Gene Symbol: MME
3 Cross references
236 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSDCDG00000029945
Gene Symbol: LOC114800846
3 Cross references
210 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSDCDG00000005020
Gene Symbol: LOC114792033
3 Cross references
212 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSDCDG00000006619
Gene Symbol: LOC114793593
2 Cross references
161 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSDCDG00000001030
Gene Symbol: LOC114784187
2 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSDCDG00000030210
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSDCDG00000029216
Gene Symbol: LOC114794667
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSDCDG00000004583
Gene Symbol: LOC114785221
3 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).